Unknown

Dataset Information

A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers.


ABSTRACT: Human epidermal growth factor receptor 2 (HER2), as a receptor tyrosine kinase of EGF receptor family, whose mutation is often associated with even if less frequency but poor prognosis and shorter survival in pulmonary malignant tumor. HER2 status include mutation, overexpression, amplification and also some rare genotypes, detected by next generation sequencing (NGS), immunohistochemistry (IHC), and also fluorescence in situ hybridization (FISH). Different genotypes represent different therapeutic targets and indicate different clinical prognosis concluded by previous studies. Unfortunately, no standard guidelines for first-line treatment are widely recognized, and current therapeutic schedules include chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Especially for patient

SUBMITTER: Wu R 

PROVIDER: S-EPMC8264687 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature